Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement

NCT00448864 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
75
Enrollment
INDUSTRY
Sponsor class

Stopped Experience gained from this study is sufficient to design and facilitate the follow-on study.

Conditions

Interventions

Sponsor

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)